Non-Cholinergic Strategies for Treating and Preventing Alzheimer’s Disease

Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’sdisease in the United States and the public health impact ofdelaying disease onset. Am J Public Health 1998 Sep; 88(9): 1337–42 Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer’sdisease. Drugs 2001; 61(1): 41–52 Rocca P, Cocuzza E, Marchiaro L, et al. Donepezil in the treatment of Alzheimer’s disease: long-term efficacy and safety. Prog Neuropsychopharmacol Biol Psychiatry 2002 Feb; 26(2): 369–73 Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2001 Sep; 16(9): 852–7 Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug 14; 57(3): 489–95 Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 1997: CD001191 Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998 May; 50(5): 1222–30 McLendon BM, Doraiswamy PM. Defining meaningful change in Alzheimer’s disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999 Spring; 12(1): 39–48 Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001 Aug 14; 57(3): 481–8 Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001 Aug 28; 57(4): 613–20 Muir JL. Acetylcholine, aging, and Alzheimer’s disease. Pharmacol Biochem Behav 1997 Apr; 56(4): 687–96 Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease: new hypothesis and new therapeutic strategies. Arch Neurol 1997 Oct; 54(10): 1234–40 Emilien G, Beyreuther K, Masters CL, et al. Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol 2000 Apr; 57(4): 454–9 Krieglstein J, Lippert K, Poch G. Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology 1996; 35(12): 1737–42 Watkins JC, Evans RH. Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol 1981; 21: 165–204 Greenamyre JT, Maragos WF, Albin RL, et al. Glutamate transmission and toxicity in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12(4): 421–30 Arias C, Arrieta I, Tapia R. Beta-amyloid peptide fragment 25–35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices. J Neurosci Res 1995 Jul 1; 41(4): 561–6 Goodwin JL, Uemura E, Cunnick JE. Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. Brain Res 1995 Sep 18; 692(1–2): 207–14 Lees GJ. Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience 1993 May; 54(2): 287–322 Harris ME, Wang Y, Pedigo Jr NW, et al. Amyloid beta peptide (25–35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem 1996 Jul; 67(1): 277–86 Liang Z, Valla J, Sefidvash-Hockley S, et al. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer’s disease patients. J Neurochem 2002 Mar; 80(5): 807–14 Topper R, Gehrmann J, Banati R, et al. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol (Berl) 1995; 89(1): 23–8 Chen HS, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992 Nov; 12(11): 4427–36 Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 1995 Oct 6; 293(3): 267–70 Wenk GL, Danysz W, Mobley SL. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res 1994 Aug 29; 655(1–2): 7–11 Headley PM, Grillner S. Excitatory amino acids and synaptic transmission: the evidence for a physiological function. Trends Pharmacol Sei 1990 May; 11(5): 205–11 Misztal M, Frankiewicz T, Parsons CG, et al. Learning deficits induced by chronic intraventricular infusion of quinolinic acid: protection by MK-801 and memantine. Eur J Pharmacol 1996 Jan 18; 296(1): 1–8 Kornhuber J, Weiler M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997 Jan 15; 41(2): 135–44 Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999 Jun; 38(6): 735–67 Seif el Nasr M, Peruche B, Rossberg C, et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990 Aug 21; 185(1): 19–24 Parsons CG, Danysz W, Bartmann A, et al. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 1999 Jan; 38(1): 85–108 Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, et al. Memantine prevents beta-amyloid-induced neurotoxicity and learning impairment in rats [abstract]. Neurobiol Aging 2002; 23: S102 Danysz W, Möbius H–J, Parsons CG, et al. Memantine provides neuroprotection in animal models at therapeutically relevant doses [abstract]. Am J Geriatr Psychiatry 2002; 10(2 Suppl. 1): 1–122 Danysz W, Parsons CG, Möbius HJ, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease: a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000; 2: 85–97 Reisberg B, Stöffler A, Ferris S, et al. A placebo-controlled study of memantine in advanced Alzheimer’s disease [abstract]. Am J Geriatr Psychiatry 2002; 10(2 Suppl. 1): 1–122 Wimo A, Winblad B, Stöffler A, et al. Effect of long-term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer’s disease: results of a 28-week, randomized, double-blind, placebo-controlled study [abstract]. Neurobiol Aging 2002; 23: S44 Reisberg B, Ferris S, Möbius HJ, et al. Long-term treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderately severe-to-severeAlzheimer’s disease [abstract]. Neurobiol Aging 2002; 23: S555 Galasko D. New approaches to diagnose and treat Alzheimer’s disease: a glimpse of the future. Clin Geriatr Med 2001 May; 17(2): 393–410 Teunissen CE, de Vente J, Steinbusch HW, et al. Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002 Jul–Aug; 23(4): 485–508 Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology 1995 Jan; 45(1): 51–5 Doraiswamy PM, Bieber F, Kaiser L, et al. The Alzheimer’sDisease Assessment Scale: patterns and predictors of baselinecognitive performance in multicenter Alzheimer’s disease trials.Neurology 1997 Jun; 48(6): 1511–7 Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial ofindomethacin in Alzheimer’s disease. Neurology 1993 Aug;43(8): 1609–11 Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlledtrial of diclofenac/misoprostol in Alzheimer’s disease.Neurology 1999 Jul 13; 53(1): 197–201 Sainati SM, Ingram DM, Talwalker S, et al. Results of a double-blind,randomized, placebo-controlled study of celecoxib inthe treatment of progression of Alzheimer’s disease. 6th InternationalStockholm/Springfield Meeting on Advances inAlzheimer Therapy; 2000 Apr 5–8; Stockholm, Sweden Aisen P, Schafer K, Grundman M, et al. Results of a multicentertrial of rofecoxib and naproxen in Alzheimer’s disease [abstract].Neurobiol Aging 2002; 23: S429 Block G, Norman B, Liu G, et al. A clinical trial of rofecoxib,a selective COX-2 inhibitor, for the treatment of Alzheimer’sdisease [abstract]. Neurobiol Aging 2002; 23: S73 in t’Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidalantiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001 Nov 22; 345(21): 1515–21 Breteler MM, in t’Veld BA, Hofman A, et al. A beta-42 peptidelowering NSAIDs and Alzheimer’s disease. Neurobiol Aging2002; 23: S286 Wolfson C, Perrault A, Moride Y, et al. A case-control analysisof nonsteroidal anti-inflammatory drugs and Alzheimer’s disease:are they protective? Neuroepidemiology 2002 Mar–Apr;21(2): 81–6 Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer’sdisease and duration of NSAID use. Neurology 1997 Mar; 48(3): 626–32 Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalenceof AD in users of NSAIDs and H2 receptor antagonists: theCache County study. Neurology 2000 Jun 13; 54(11): 2066–71 Breitner JC, Zandi PP. Do nonsteroidal antiinflammatory drugsreduce the risk of Alzheimer’s disease? N Engl J Med 2001Nov 22; 345(21): 1567–8 Beal MF. Aging, energy, and oxidative stress in neurodegenerativediseases. Ann Neurol 1995 Sep; 38(3): 357–66 Benzi G, Moretti A. Are reactive oxygen species involved inAlzheimer’s disease? Neurobiol Aging 1995 Jul–Aug; 16(4):661–74 McGeer PL, McGeer EG. The inflammatory response system ofbrain: implications for therapy of Alzheimer and other neurodegenerativediseases. Brain Res Brain Res Rev 1995 Sep; 21(2): 195–218 McGeer PL, McGeer EG. Anti-inflammatory drugs in the fightagainst Alzheimer’s disease. Ann N Y Acad Sci 1996 Jan 17;777: 213–20 Oken BS, Storzbach DM, Kaye JA. The efficacy of ginkgobiloba on cognitive function in Alzheimer disease. Arch Neurol 1998 Nov; 55(11): 1409–15 Wettstein A. Cholinesterase inhibitors and gingko extracts: arethey comparable in the treatment of dementia? Comparisonof published placebo-controlled efficacy studies of at least sixmonths’ duration. Phytomedicine 2000 Jan; 6(6): 393–401 van Dongen MC, van Rossum E, Kessels AG, et al. The efficacyof ginkgo for elderly people with dementia and age-associatedmemory impairment: new results of a randomized clinicaltrial. J Am Geriatr Soc 2000 Oct; 48(10): 1183–94 Schreiter Gasser U, Gasser T. A comparison of cholinesteraseinhibitors and ginkgo extract in treatment of Alzheimer dementia.Fortschr Med Orig 2001 Nov 29; 119(3–4): 135–8 Stough C, Clarke J, Lloyd J, et al. Neuropsychological changesafter 30-day ginkgo biloba administration in healthy participants.Int J Neuropsychopharmacol 2001 Jun; 4(2): 131–4 Solomon PR, Adams F, Silver A, et al. Ginkgo for memoryenhancement: a randomized controlled trial. JAMA 2002 Aug 21; 288(7): 835–40 Tuszynski MH, Sang H, Yoshida K, et al. Recombinant humannerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 1991 Nov; 30(5): 625–36 Olson L. NGF and the treatment of Alzheimer’s disease. ExpNeurol 1993 Nov; 124(1): 5–15 Ringheim GE. Glial modulating and neurotrophic properties ofpropentofylline and its application to Alzheimer’s disease andvascular dementia. Ann N Y Acad Sci 2000 Apr; 903: 529–34 Shimazu S, Tachikawa N, Iwamoto N, et al. The neurotrophic action and brain protective effect of cerebrolysin [abstract]. Neurobiol Aging 1992; 13 Suppl. 1: S50 Albrecht E, Hingel S, Crailsheim K, et al. The effects of cerebrolysin on survival and sprouting of neurons from cerebral hemispheres and from the brain stem of chicken embryos in vitro [abstract]. Neurobiol Aging 1992; 13 Suppl. 1: S127 Bae CY, Cho CY, Cho K, et al. A double-blind, placebo-controlled, multicenter study of cerebrolysin for Alzheimer’s disease. J Am Geriatr Soc 2000 Dec; 48(12): 1566–71 Ruther E, Ritter R, Apecechea M, et al. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 1994 Jan; 27(1): 32–40 Ruther E, Ritter R, Apecechea M, et al. Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of cerebrolysin therapy. J Neural Transm 2000; 107(7): 815–29 Panisset M, Gauthier S, Moessler H, et al. Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebocontrolled trial with a neurotrophic agent. J Neural Transm 2002 Jul; 109(7–8): 1089–104 Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease: Donepezil Study Group. Neurology 1998 Jan; 50(1): 136–45 Rainer M, Mucke HA, Kruger-Rainer C, et al. Cognitive relapse after discontinuation of drug therapy in Alzheimer’s disease: cholinesterase inhibitors versus nootropics. J Neural Transm 2001; 108(11): 1327–33 Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemiaaccelerates the Alzheimer’s amyloid pathology in a transgenicmouse model. Neurobiol Dis 2000 Aug; 7(4): 321–31 Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia.Lancet 2000 Nov 11; 356(9242): 1627–31 Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalenceof Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000 Oct; 57(10): 1439–43 Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002 Feb; 59(2): 223–7 Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001 May 8; 98(10): 5856–61 Sterzer P, Meintzschel F, Rosler A, et al. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 2001 Dec 1; 32(12): 2817–20 Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001 Jun; 21(6): 767–9 Barrett AM. Probable Alzheimer’s disease: gender-related issues. J Gend Specif Med 1999 Jan–Feb; 2(1): 55–60 Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985 Aug; 89(2): 484–90 Toran-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 1992 May 15; 89(10): 4668–72 Henderson VW. Estrogen, cognition, and a woman’s risk of Alzheimer’s disease. Am J Med 1997 Sep 22; 103(3A): 11S–8S Birge SJ. The role of estrogen in the treatment and prevention of dementia: introduction. Am J Med 1997 Sep 22; 103(3A): 1S–2S Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrineresponse to transdermal estrogen in postmenopausal womenwith Alzheimer’s disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999 Aug; 24(6): 657–77 Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000 Jun 13; 54(11): 2061–6 Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000 Jan 25; 54(2): 295–301 Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial: Alzheimer’s Disease Cooperative Study. JAMA 2000 Feb 23; 283(8): 1007–15 Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol 1994 Aug 1; 140(3): 256–61 Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer’s disease cases and nondemented control subjects. Arch Neurol 1994 Sep; 51(9): 896–900 Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen duringmenopause on risk and age at onset of Alzheimer’s disease. Lancet 1996 Aug 17; 348(9025): 429–32 Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacementtherapy and Alzheimer’s disease in the Italian Longitudinal Study on Aging. Neurology 1998 Apr; 50(4): 996–1002 Writing Group for the Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3): 321–33 Markesbery WR, Carney JM. Oxidative alterations in Alzheimer’s disease. Brain Pathol 1999 Jan; 9(1): 133–46 McCaddon A, Davies G, Hudson P, et al. Total serum homocysteinein senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998 Apr; 13(4): 235–9 Lehmann M, Gottfries CG, Regland B. Identification of cognitiveimpairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 1999 Jan–Feb; 10(1): 12–20 Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002 Feb 14; 346(7): 476–83 Paleologos M, Cumming RG, Lazarus R. Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol 1998 Jul 1; 148(1): 45–50 Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitaminC supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998 Sep; 12(3): 121–6 Sano M, Ernesto C, Thomas RG, et al. A controlled trial ofselegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. N Engl J Med 1997 Apr 24; 336(17): 1216–22 Schenk D, Barbour R, Dunn W, et al. Immunization with amyloidbetaattenuates Alzheimer-disease-like pathology in the PDAPPmouse. Nature 1999 Jul 8; 400(6740): 173–7 Elan Corporation & Wyeth-Ayerst Laboratories, 2002. (Data onfile) Lee JY, Mook-Jung I, Koh JY. Histochemically reactive zincin plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci 1999 Jun 1; 19(11): RC10 Smith MA, Harris PL, Sayre LM, et al. Iron accumulation inAlzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997 Sep 2; 94(18): 9866–8 Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 1998 Jun 11; 158(1): 47–52 Suh SW, Jensen KB, Jensen MS, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer’s diseased brains. Brain Res 2000 Jan 10; 852(2): 274–8 Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer’s disease Abeta amyloid deposits by biometal depletion. J Biol Chem 1999 Aug 13; 274(33): 23223–8 Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 2001 Jun; 30(3): 665–76 Regland B, Lehmann W, Abedini I, et al. Treatment of Alzheimer’sdisease with clioquinol. Dement Geriatr Cogn Disord 2001 Nov–Dec; 12(6): 408–14 Prama Biotechnology, 2002. (Data on file) Gualtieri F, Manetti D, Romanelli MN, et al. Design and studyof piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des 2002; 8(2): 125–38 Danysz W, Parsons CG, Quack G. NMDA channel blockers: memantine and amino-aklylcyclohexanes: in vivo characterization. Amino Acids 2000; 19(1): 167–72 Hoerr R, Noeldner M. Ensaculin (KA-672 HC1): a multi-transmitter approach to dementia treatment. CNS Drug Rev 2002 Sum; 8(2): 143–58 Schneider LS, Farlow MR, Henderson VW, et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer’s disease. Neurology 1996 Jun; 46(6): 1580–4